Market Cap | 19.14M | P/E | - | EPS this Y | 50.40% | Ern Qtrly Grth | - |
Income | -25.17M | Forward P/E | -0.64 | EPS next Y | 21.50% | 50D Avg Chg | 5.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
Dividend | N/A | Price/Book | 0.42 | EPS next 5Y | - | 52W High Chg | -65.00% |
Recommedations | 2.00 | Quick Ratio | 1.89 | Shares Outstanding | 2.84M | 52W Low Chg | 25.00% |
Insider Own | 3.53% | ROA | -47.68% | Shares Float | 2.33M | Beta | 1.85 |
Inst Own | 11.11% | ROE | -86.82% | Shares Shorted/Prior | 125.22K/51.33K | Price | 0.65 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 187,970 | Target Price | 31.67 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 23,068 | Change | 0.78% |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Roth MKM | Buy | Apr 12, 24 |
Maxim Group | Buy | Mar 26, 24 |
HC Wainwright & Co. | Buy | Dec 14, 23 |
Roth MKM | Buy | Apr 18, 23 |
Oppenheimer | Outperform | Mar 24, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Foster Jonathan P. | Chief Financial Offi.. Chief Financial Officer | Dec 26 | Buy | 0.69 | 28,986 | 20,000 | 80,556 | 12/27/23 |
George Robert E. | Director Director | Dec 26 | Buy | 0.69 | 14,493 | 10,000 | 14,660 | 12/27/23 |
KLEMP WALTER V | CEO and President CEO and President | Dec 26 | Buy | 0.69 | 188,404 | 129,999 | 680,880 | 12/27/23 |
KLEMP WALTER V | CEO and President CEO and President | Nov 25 | Buy | 1.2807 | 45,000 | 57,632 | 409,890 | 11/28/22 |
KLEMP WALTER V | CEO and President CEO and President | Nov 21 | Buy | 1.1496 | 22,500 | 25,866 | 364,890 | 11/23/22 |
KLEMP WALTER V | CEO and President CEO and President | Nov 16 | Buy | 1 | 109,955 | 109,955 | 342,390 | 11/18/22 |